Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

The Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable” until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Molecular Oncology
المؤلفون الرئيسيون:	Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2025-02-01
الموضوعات:	fedratinib KRAS MRTX1133 pancreatic cancer sotorasib trametinib
الوصول للمادة أونلاين:	https://doi.org/10.1002/1878-0261.13751

مواد مشابهة

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma
حسب: Analia Meilerman Abuelafia, وآخرون
منشور في: (2025-07-01)

Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRASG12D-targeted inhibitor MRTX1133
حسب: WANG Gaoming, وآخرون
منشور في: (2025-06-01)

Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms
حسب: Mari C. Vázquez-Borrego, وآخرون
منشور في: (2023-12-01)

Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer
حسب: Jeffrey Xiao, وآخرون
منشور في: (2025-05-01)

Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
حسب: Jonas Frederik Schmidt, وآخرون
منشور في: (2024-09-01)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
حسب: XuSha Zhou, وآخرون
منشور في: (2021-09-01)

Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
حسب: Wei Lu, وآخرون
منشور في: (2024-12-01)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
حسب: Brazel D, وآخرون
منشور في: (2022-11-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
حسب: K. K. Laktionov, وآخرون
منشور في: (2024-05-01)

Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
حسب: Warnecke B, وآخرون
منشور في: (2024-12-01)

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
حسب: Prasanna Srinivasan Ramalingam, وآخرون
منشور في: (2025-07-01)

Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report
حسب: Jiao Yang, وآخرون
منشور في: (2024-06-01)

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
حسب: Hyungkyung Shin, وآخرون
منشور في: (2025-05-01)

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
حسب: Chungui Xu, وآخرون
منشور في: (2024-11-01)

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
حسب: Prakash Kulkarni, وآخرون
منشور في: (2023-10-01)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
حسب: Alessandro Inno, وآخرون
منشور في: (2023-06-01)

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C
حسب: Masaoki Ito, وآخرون
منشور في: (2025-05-01)

MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
حسب: Junwei Zou, وآخرون
منشور في: (2025-02-01)

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
حسب: Steven H Lin, وآخرون
منشور في: (2022-01-01)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
حسب: Kohei Okada, وآخرون
منشور في: (2023-01-01)

Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
حسب: Raquel Arantes Megid, وآخرون
منشور في: (2025-01-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
حسب: Metin Eser, وآخرون
منشور في: (2024-11-01)

Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function
حسب: Lorenzo M. Fernandes, وآخرون
منشور في: (2023-09-01)

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report
حسب: Masafumi Saiki, MD, وآخرون
منشور في: (2024-01-01)

Sotorasib Is Not Effective in a KRAS‐Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple Gene Co‐Mutations
حسب: Takayuki Suetsugu, وآخرون
منشور في: (2025-05-01)

Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
حسب: Katherine I. Zhou, MD, PhD, وآخرون
منشور في: (2024-05-01)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
حسب: Parvin Begum, MBChB.(Hons), وآخرون
منشور في: (2021-09-01)

Investigation of potential KRASG12D inhibitors: a comparative study between MRTX1133 and natural compounds via computational structural biology approaches
حسب: Safiye Merve Bostancioglu, وآخرون
منشور في: (2025-07-01)

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisResearch in context
حسب: Sophie M. Ernst, وآخرون
منشور في: (2024-04-01)

Interaction Mechanisms of KRAS G12C Inhibitors (Sotorasib and Adagrasib) with Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies
حسب: Junsong Qin, وآخرون
منشور في: (2025-08-01)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
حسب: Takanori Ito, MD, وآخرون
منشور في: (2023-05-01)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
حسب: Brazel D, وآخرون
منشور في: (2023-04-01)

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
حسب: Pierre-Antoine Laurent, وآخرون
منشور في: (2023-10-01)

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
حسب: Ander Puyalto, وآخرون
منشور في: (2024-04-01)

Bluegrass Billbug Sphenophorus parvulus Gyllenhal (Insecta: Coleoptera: Curculionidae: Dryophthorinae)
حسب: Luis F. Aristizábal, وآخرون
منشور في: (2016-06-01)

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
حسب: Alessandro Tubita, وآخرون
منشور في: (2025-09-01)

The role of KRAS splice variants in cancer biology
حسب: Cristina Nuevo-Tapioles, وآخرون
منشور في: (2022-11-01)

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
حسب: Szu-Aun Long, وآخرون
منشور في: (2024-05-01)

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
حسب: Hiroshi Kotani, وآخرون
منشور في: (2024-07-01)

Ponorni kontaktni kras Zrenjskega ravnika, Istra, Hrvaška
حسب: Uroš Stepišnik
منشور في: (2022-12-01)